Extracellular vesicles derived from bone marrow MSCs have been shown to attenuate the inflammatory response of CRPS by inhibiting pro-inflammatory factors (e.g., TNF-α and IL-6). This evidence concerns the gene IL6 and complex regional pain syndrome.